Investing.com - Silence Therapeutics (NASDAQ: SLN) reported fourth quarter EPS of $0.46, $0.47 better than the analyst estimate of $-0.01. Revenue for the quarter came in at $18M versus the consensus estimate of $20.37M.
Silence Therapeutics's stock price closed at $9.66. It is down -33.65% in the last 3 months and down -43.18% in the last 12 months.
Silence Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Silence Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Silence Therapeutics's Financial Health score is "fair performance".
Check out Silence Therapeutics's recent earnings performance, and Silence Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar